Evidence map›Paper›PMID 33469573›Full record

ArticleResearch square2021

COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone.

Aartik Sarma, Stephanie A Christenson, Eran Mick, Catherine DeVoe, Thomas Deiss, Angela Oliveira Pisco, Rajani Ghale, Alejandra Jauregui, Ashley Byrne, Farzad Moazed and 21 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 27 citations in OpenAlex.

  1. Impact of e-cigarette aerosol on primary human alveolar epithelial type 2 cells.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 4 institutions in 1 country.

Aartik SarmaDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Stephanie A ChristensonDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Eran MickDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Catherine DeVoeDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
Thomas DeissDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
Angela Oliveira PiscoChan Zuckerberg Biohub, San Francisco, CA, USA.
Rajani GhaleDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Alejandra JaureguiDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
Ashley ByrneChan Zuckerberg Biohub, San Francisco, CA, USA.
Farzad MoazedDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Natasha SpottiswoodeDepartment of Medicine, University of California, San Francisco, CA, USA.
Pratik SinhaDepartment of Anesthesia, Washington University, Saint Louis, Missouri, MO, USA.
Beth Shoshana ZhaDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Norma NeffChan Zuckerberg Biohub, San Francisco, CA, USA.
Michelle TanChan Zuckerberg Biohub, San Francisco, CA, USA.
Paula Hayakawa SerpaDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
K Mark AnselDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA.
Jennifer G WilsonDepartment of Emergency Medicine, Stanford University, Palo Alto, CA, USA.
Aleksandra LeligdowiczDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
Emily R SiegelSchool of Medicine, University of California, San Francisco, CA, USA.
Marina SirotaDivision of Rheumatology, University of California, San Francisco, CA, USA.
Joseph L DeRisiChan Zuckerberg Biohub, San Francisco, CA, USA.
Michael A MatthayDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
COMET Consortium
Carolyn M HendricksonDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Kirsten N KangelarisDepartment of Medicine, University of California, San Francisco, CA, USA.
Matthew F KrummelDepartment of Pathology, University of California, San Francisco, CA, USA.
Prescott G WoodruffDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
David J ErleDepartment of Medicine, University of California, San Francisco, CA, USA.
Carolyn S CalfeeDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA.
Charles R LangelierDivision of Infectious Diseases, University of California, San Francisco, CA, USA.
University of California, San Francisco · USChan Zuckerberg Initiative (United States) · USStanford University · USWashington University in St. Louis · US

Funding

BIOLOGY OF INFECTIOUS DISEASES TRAINING PROGRAMT32AI007641 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY · 2000 to 2026
$6.9M
Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
Profiling the Lung Transcriptome for Precision Diagnosis of Respiratory Infections using Host/Pathogen Metagenomic SequencingK23HL138461 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANGELIER, CHARLES · 2018 to 2021
$718k
Transcriptomic signatures of airway inflammation in acute respiratory diseasesF32HL151117 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SARMA, AARTIK · 2020 to 2022
$206k
NHLBI NIH HHS F32 HL151117NHLBI NIH HHS K23 HL138461NHLBI NIH HHS K24 HL137013NHLBI NIH HHS R35 HL140026NIAID NIH HHS T32 AI007641
6 · The paper itself

Abstract

We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with the acute respiratory distress syndrome (ARDS) from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 was characterized by impaired interferon-stimulated gene expression (ISG). We found that the relationship between SARS-CoV-2 viral load and expression of ISGs was decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone.

Identifiers

PMID33469573
PMCPMC7814832
OpenAlexW3125338983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.